drugset / Trial / NCT01869725
Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT
NaSingle-groupOpen-labelDiagnostic
Summary
This clinical trial studies gallium Ga 68-edotreotide positron emission tomography (PET)/computed tomography (CT) compared with indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosing patients with neuroendocrine tumors and other somatostatin receptor positive tumors. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT, may help find and diagnose somatostatin receptor positive neuroendocrine tumors. It is not yet known whether Ga 68-edotreotide PET/CT is as effective as indium In 111 pentetreotide plus contrast-enhanced CT (or MRI) in diagnosis and staging of patients with neuroendocrine tumors.
Timeline
- Start
- 2013-04-01
- Primary completion
- 2018-12-26
- Completion
- 2018-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-DOTATOC | Peptide | — | Intravenous |